All Very Strange

HC ACL folks

A review of the January ACL statement about the Phase 3 trial results and an examination of other publicly available data for colorectal cancer drug trial results; and recent FDA approvals, suggests to me that if the Russian patient results were excluded - the ACL HyACT drug produced better PFS & OS results than recent FDA approvals? I'm not aware of any VALID reasons why Russian trial patients should have such different results.
So; we now have a company with a market cap of about $20 million; instead of >$0.5 billion if Phase 3 had been 'successful'.

And, we have Mylan buying Arixtra and the authorised fonda generic for >US$220 million. So; the ACL fonda asset has to be worth ????

So; 6 cents/share seems all 'very strange' to me.